Hologic (NASDAQ:HOLX) announced its acquisition of Gen-Probe (NASDAQ:GPRO) in a cash deal valued at $82.75 a share, which represents a 20% premium over the company’s Friday close.The company expects the deal to add $0.20 per share to adjusted EPS in its first year after the closing of the deal.Hologic expects to fund the deal through cash, and added term loans.